Compare FUN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUN | PVLA |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2023 | 2013 |
| Metric | FUN | PVLA |
|---|---|---|
| Price | $8.36 | $122.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | $19.69 | ★ $231.25 |
| AVG Volume (30 Days) | ★ 3.8M | 192.5K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | ★ 14.80% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,100,289,000.00 | $42,810,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 14.45 | ★ 65.28 |
| 52 Week Low | $7.95 | $68.96 |
| 52 Week High | $27.37 | $161.38 |
| Indicator | FUN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 26.96 | 37.86 |
| Support Level | N/A | $120.61 |
| Resistance Level | $18.13 | $136.35 |
| Average True Range (ATR) | 0.69 | 7.26 |
| MACD | -0.23 | -0.98 |
| Stochastic Oscillator | 9.90 | 21.87 |
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS. The parks are family-oriented, with recreational facilities for people of all ages, and provide clean and attractive environments with exciting rides and immersive entertainment. The Company generates revenue from sales of admission to the amusement parks and water parks, from purchases of food, merchandise and games both inside and outside the parks, from the sale of accommodations and other extra-charge.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.